Form 4: Iovance Biotherapeutics Chief Medical Officer Friedrich Graf Finckenstein Reports Stock Transactions
SEC Form 4 Filing
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent withholding of shares for tax obligations.
Summary
- On March 3, 2025, Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, had restricted stock units (RSUs) vest, resulting in the acquisition of 62,497 shares of common stock.
- The issuer withheld 33,470 shares to satisfy tax obligations at a price of $4.04 per share.
- Following these transactions, Graf Finckenstein directly owns 92,913 shares of common stock.
- Additionally, 3,907 RSUs from a grant on March 2, 2023, vested, and 58,590 RSUs from a grant on March 1, 2024, vested.
- After the transactions, Graf Finckenstein holds 15,626 RSUs from the March 2, 2023 grant and 70,317 RSUs from the March 1, 2024 grant.
Sentiment
Score: 5
Explanation: This is a neutral event, reflecting routine compensation and tax obligations.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 2023-03-02 | Date of original RSU grant, remainder of which are now 15,626 RSUs. |
| 2024-03-01 | Date of original RSU grant, remainder of which are now 70,317 RSUs. |
| 2025-03-03 | Date of transaction: vesting of RSUs and withholding of shares for taxes. |
| 2025-03-05 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.